about
Alumis Inc is a clinical-stage biopharmaceutical company with an initial focus on developing its two Tyrosine Kinase 2 ("TYK2") inhibitors: envudeucitinib ("envu"), an allosteric TYK2 inhibitor for the treatment of PsO and SLE; and A-005, a central n...
Read More
27.98
-0.68
(-2.37%)
694.5K
XNAS Volume
XNAS 20 Jul, 2026 5:30 PM (EDT)
Board Meeting
The next board meeting for Alumis Inc is on 30 Jul 2026 for the purpose of Alumis Inc Annual General Meeting for 2026
See details
Not Eligible
Expensive Valuation
Technically Moderately Bullish
Alumis Inc Live Price Chart
Switch to TradingView
Loading Fundamental data..
Loading data..